These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 1893005)

  • 41. Plasma-zinc concentration in patients with bronchogenic carcinoma.
    Davies IJ
    Lancet; 1972 Jan; 1(7742):149. PubMed ID: 4109007
    [No Abstract]   [Full Text] [Related]  

  • 42. Unstable osmolar homeostasis with and without renal sodium wastage.
    SCHWARTZ E; FOGEL RL; CHOKAS WV; PANARIELLO VA
    Am J Med; 1962 Jul; 33():39-53. PubMed ID: 13909692
    [No Abstract]   [Full Text] [Related]  

  • 43. Conjugation pathways in human bronchial carcinoma cell lines.
    Gibby EM; Mehta R; Ellison M; Cohen GM
    Biochem Pharmacol; 1981 Dec; 30(24):3333-6. PubMed ID: 7326043
    [No Abstract]   [Full Text] [Related]  

  • 44. Highlight report: gene dose response in N-acetylation capacity.
    Selinski S
    Arch Toxicol; 2017 Dec; 91(12):4019-4020. PubMed ID: 29185025
    [No Abstract]   [Full Text] [Related]  

  • 45. [Anatomico-pathological observations of the peculiarities of lung carcinoma-polymorphism, paradoxes and exaggerations].
    FROBOESE C
    Z Gesamte Inn Med; 1951 Jun; 6(11-12):321-30. PubMed ID: 14856152
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparing mindfulness based cognitive therapy and traditional cognitive behavior therapy with treatments as usual on reduction of major depressive disorder symptoms.
    Omidi A; Mohammadkhani P; Mohammadi A; Zargar F
    Iran Red Crescent Med J; 2013 Feb; 15(2):142-6. PubMed ID: 23682326
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acetylator phenotype in patients with lung carcinoma--a negative report.
    Burgess EJ; Trafford JA
    Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genetic polymorphism of N-acetyltransferase 2 in patients with esophageal cancer.
    Shibuta J; Eto T; Kataoka A; Inoue H; Ueo H; Suzuki T; Barnard GF; Mori M
    Am J Gastroenterol; 2001 Dec; 96(12):3419-24. PubMed ID: 11774959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
    Grant DM; Mörike K; Eichelbaum M; Meyer UA
    J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
    Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
    Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Acetylation polymorphism in lung cancer].
    Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
    An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.